neuroscience-2018-posters-abstracts

Page 48

Notes:

allied

academies

Volume 2

June 11-13, 2018 | London, UK

Neurology and Neuroscience

International Conference on

Effects of sugammadex with rocuronium or vecuronium in neurons in primary culture

Juan Campos-Campos, Adrian Jorda, Constanza Aldasoro, Martin Aldasoro, Patricia Marchio, Sol Guerra-Ojeda, Mª Dolores Mauricio,

Antonio Iradi, Jose M Vila

and

Soraya L. Valles

University of Valencia, Spain

ugammadex (SUG) rapidly reverses steroidal NMB agents

after anaesthesia. Rocuronium (ROC) and Vecuronium

(VEC) are the most currently used steroidal non-depolarizing

neuromuscular blocking (MNB) agents. The aim of our study

was to evaluate the SUG effects and also in combination with

ROC or VEC. Using MTT, CASP-3 activity and Western-blot

we determined the toxicity of SUG, ROC or VEC in neurons in

primary culture. Apoptosis/necrosis was detected after SUG

addition with increase in cytochrome C (CytC), apoptosis-

inducing factor (AIF), Smac/Diablo and Caspase 3 (CASP-3)

protein expression. ROC and VEC prevent these SUG effects

in neurons in primary culture. SUG encapsulates NMB drugs

and the protection of ROC or VEC could explain it. Control

of SUG doses should be necessary to prevent free SUG in

plasma, obviously when BBB is damaged, such as Alzheimer’s

disease or in development brain. A balance between SUG, ROC

or VEC should prevent risk of cell damage inside the brain.

Speaker Biography

Juan Campos-Campos finished his studies in Physiotherapy in 2010 in the

Faculty of Physiotherapy in the University of Valencia. His Master was in the

Department of Anatomy, in the School of Medicine (2013). He Starts his PhD

in 2014 in the Department of Physiology, University of Valencia, Spain, with

Doctor Soraya L. Valles. The title of the PhD will be: “Effect of Sugammadex

and Rocuronium and Vecuronium in neural cells in primary cultures”. Also he is

studding Medicine (in the 3 year). He will finished his PhD in the end of 2018.